Astrana Health price target raised to $70 from $60 at BTIG

BTIG analyst David Larsen raised the firm’s price target on Astrana Health (ASTH) to $70 from $60 and keeps a Buy rating on the shares. The news from Humana (HUM) regarding its position in Star ratings, with only 25% of members in Medicare Advantage plans above 4 Stars, highlights the value that high-quality entities like Astrana can provide while also continuing to report impressive cost trends, the analyst tells investors in a research note. With the heightened scrutiny over stars ratings and bonus payments, focus on the member experience and satisfaction is even more crucial, and Astrana excels in primary care, the firm added.